Vestmark Advisory Solutions Inc. Takes $545,000 Position in Becton, Dickinson and Company $BDX

Vestmark Advisory Solutions Inc. purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 2,911 shares of the medical instruments supplier’s stock, valued at approximately $545,000.

A number of other institutional investors have also recently bought and sold shares of the business. SOA Wealth Advisors LLC. raised its stake in shares of Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the period. Activest Wealth Management increased its holdings in Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 97 shares during the last quarter. Bell Investment Advisors Inc raised its position in Becton, Dickinson and Company by 474.1% in the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 128 shares during the period. Cornerstone Planning Group LLC boosted its stake in Becton, Dickinson and Company by 463.3% in the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 139 shares during the last quarter. Finally, Grey Fox Wealth Advisors LLC bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at approximately $32,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 2.5%

Shares of BDX opened at $176.49 on Friday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The stock has a market cap of $50.25 billion, a PE ratio of 28.79, a P/E/G ratio of 13.12 and a beta of 0.25. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The business’s 50-day moving average price is $196.07 and its 200-day moving average price is $192.20.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating the consensus estimate of $2.81 by $0.10. The company had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. Becton, Dickinson and Company’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its board has authorized a share buyback plan on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bertram L. Scott sold 953 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the transaction, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. The trade was a 2.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 3,416 shares of company stock worth $675,557. Insiders own 0.40% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the subject of several research reports. TD Cowen increased their price objective on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a report on Wednesday, February 11th. Zacks Research cut Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 11th. Bank of America lifted their price objective on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a report on Monday, January 5th. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Royal Bank Of Canada set a $172.00 target price on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Five equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus target price of $195.46.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.